Drug disposition in obese humans. An update.
Drug disposition for many drugs has now been studied in obese individuals and some general conclusions can be drawn. Absorption of drugs evaluated to date is unchanged due to obesity. Apparent volume of distribution is greatly increased for some drugs including most benzodiazepines, thiopentone, phenytoin, verapamil and lignocaine (lidocaine). Modest increases in volume of distribution have been noted for methylxanthines, aminoglycosides, vancomycin, ibuprofen, prednisolone and heparin. Distribution of digoxin, cimetidine and procainamide is unchanged in obesity. The mechanism for the increased distribution of some drugs and unchanged distribution of others in obesity is unclear at present. It may be in part due to the lipophilic character of the drug molecule; however, other complex and as yet poorly understood factors contribute to the variability in drug distribution in obese patients. Protein binding of drugs bound to albumin is not dramatically changed in obesity. In contrast, some studies report that drugs bound to alpha 1-acid glycoprotein (AAG) may have increased binding that is related to increased serum AAG concentration; however, this is not a consistent finding. Oxidative drug biotransformation is minimally changed in obesity with the exceptions of ibuprofen and prednisolone, for which clearance increases as a highly correlated function of total bodyweight. Drug conjugation uniformly increases as a function of bodyweight in obesity, with paracetamol (acetaminophen), lorazepam and oxazepam having been studied. Drug acetylation may be unchanged in obesity, with only procainamide evaluated at this time. High clearance drugs, including lignocaine, verapamil and midazolam, have no change in clearance in obese individuals compared to normal bodyweight controls. Renal clearance of drugs is little changed for some drugs evaluated (digoxin, cimetidine), and increased for others (aminoglycosides, unmetabolised procainamide). Characterisation of appropriate animal models of obesity is underway to clarify the mechanisms for these in vivo pharmacokinetic observations in obese man. Two models, the Zucker obese and the obese cafeteria-fed male Sprague-Dawley rat, have provided preliminary physiological pharmacokinetic data with evaluations of theophylline, phenobarbitone and verapamil.(ABSTRACT TRUNCATED AT 400 WORDS)
D000617:Aminoglycosides / Q000378:metabolism; D000700:Analgesics / Q000378:metabolism; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000378:metabolism; D001569:Benzodiazepines / Q000378:metabolism; D001711:Biotransformation; D002927:Cimetidine / Q000378:metabolism; D004077:Digoxin / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000378:metabolism*; D004364:Pharmaceutical Preparations / Q000097:blood / Q000378:metabolism* / Q000652:urine; D010672:Phenytoin / Q000378:metabolism; D011239:Prednisolone / Q000378:metabolism; D013874:Thiopental / Q000378:metabolism; D014700:Verapamil / Q000378:metabolism; D014970:Xanthines / Q000378:metabolism
D000617:Aminoglycosides; D000700:Analgesics; D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D004364:Pharmaceutical Preparations; D014970:Xanthines; D001569:Benzodiazepines; D010672:Phenytoin; D004077:Digoxin; D002927:Cimetidine; D011239:Prednisolone; D014700:Verapamil; D013874:Thiopental